Migraine. Migraine
Conditions
Interventions
Intervention 1: Intervention group: Intervention group received daily 200 mg of sodium valproate (a 200 mg tablet of Iran Najo Pharmaceutical Company[Iran]) and 20 mg of Atorvastatin (a 20 mg tablet o
Sponsors
Ahvaz University of Medical Sciences Research ?Assistance
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 to 65 years Having at least 3 migraine attacks per month Patients who have fewer than three attacks per month, provided that they affect high-intensity attacks and the patient's life Have a normal serum level of vitamin D3 Patients with classical migraine
Exclusion criteria
Exclusion criteria: Patients who do not sign a form of moral consent. Patients with chronic headaches (more than 15 attacks per month) Patients receiving Statin for other diseases Severe renal failure (GFR <30 ml / min) Creatine Kinase more than 3 times normal Liver enzymes more than twice the normal range The increase in liver enzymes during treatment is more than 3 times the normal Other patients who use drugs other than sodium valproate to treat their migraines and have their disease controlled or sodium valproate, and the disease is under control Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of migraine pain according to the Visual Analogue Scale (VAS). Timepoint: The measurement of pain intensity based on the Visual Analogue Scale (VAS) at the beginning of the study (before the intervention) and And one day after the intervention(4 weeks after the onset of Atorvastatin). Method of measurement: Visual Analogue Scale (VAS).;The Rate of Migraine Attacks. Timepoint: The question of the history of migraine attacks in a 8-week interval. Method of measurement: Ask The Patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Ganji
Ahvaz University of Medical Sciences
Outcome results
None listed